GlassScriptPhysician profile
Michael Overcash
NPI 1376520171
$210,153.06
in general payments reported to CMS, 2019-2025
32 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,503 · 2022: $36K · 2023: $71K · 2024: $53K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Consulting Fee: $28K · Food and Beverage: $13K · Travel and Lodging: $10K · Education: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,825.75 |
| Consulting Fee | $27,677.50 |
| Food and Beverage | $13,174.60 |
| Travel and Lodging | $10,324.86 |
| Education | $585.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $93,884.42 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $31,208.25 | 2022-2025 | Sotyktu |
| Incyte Corporation | $26,879.14 | 2021-2025 | Opzelura, Opzelura |
| Janssen Scientific Affairs, LLC | $20,501.08 | 2022 | |
| Amgen INC. | $12,944.96 | 2021-2025 | Otezla, Otezla, Enbrel |
| Arcutis Biotherapeutics, INC. | $10,886.75 | 2023-2025 | Zoryve |
| Abbvie INC. | $4,892.06 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $2,324.34 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,325.38 | 2021-2025 | Ilumya |
| Genzyme Corporation | $1,225.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $891.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $655.16 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $593.26 | 2021-2025 | |
| Leo Pharma INC. | $322.25 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $305.37 | 2022-2025 | Nemluvio, Aklief |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $272.96 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $237.24 | 2021-2025 | Bimzelx |
| Almirall LLC | $124.25 | 2022-2025 | Klisyri |
| Organon LLC | $123.26 | 2024-2025 | Hadlima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $107.03 | 2022-2024 | Targretin, Siliq, Duobrii |
| Mayne Pharma Commercial LLC | $91.67 | 2023-2025 | |
| Dermavant Sciences, INC. | $83.97 | 2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Sandoz INC. | $33.25 | 2023-2025 | Hyrimoz |
| Biofrontera INC. | $30.75 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $24.64 | 2022 | |
| Verrica Pharmaceuticals INC. | $22.51 | 2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.17 | 2025 | Spevigo |
| Epi Health, LLC | $17.66 | 2021 | |
| Myriad Genetic Laboratories, INC. | $16.99 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $14.48 | 2021 | |
| Strata Skin Sciences, INC. | $13.15 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Overcash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.